Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Issue 1002 (5th May 2009)

• Record Type: Journal Article
• Authors: Crasto, W; Jarvis, J; Hackett, E; Nayyar, V; McNally, P G; Davies, M J; Lawrence, I G
• Is Part Of: Postgraduate medical journal. Volume 85:Issue 1002(2009)
• Page Start: 219
• Page End: 222
• Publication Date: 2009-05-05
• Subjects: insulin -- U-500 -- type 2 diabetes -- insulin resistance; Medicine -- Periodicals; 610
• DOI: 10.1136/pgmj.2008.073379
• Languages: English
• ISSNs: 0032-5473

Abstract

Abstract : Some patients with type 2 diabetes mellitus (T2DM) are profoundly insulin resistant and require large insulin doses to achieve optimal glycaemic control. However, large volumes of subcutaneous conventional U-100 insulin can cause discomfort at the injection site, resulting in poor concordance with insulin therapy. One therapeutic option is the use of U-500 insulin, thus reducing the insulin volume by 80%. This review will address the practical issues associated with the use of U-500, clinical efficacy and safety aspects of this concentrated insulin, which has an important role in a subgroup of patients with T2DM.